Henry Schein, Inc. (HSIC) announced that Frederick M. Lowery will assume the role of chief executive officer on March 2 2026. Lowery, who spent the last decade as Executive Vice President and President of Laboratory Products and BioProduction at Thermo Fisher Scientific, brings more than 20 years of experience in scaling complex healthcare distribution and manufacturing businesses.
The appointment is a deliberate step to accelerate the company’s refreshed BOLD+1 strategic plan, which focuses on high‑margin specialty products and technology services. Lowery’s background in driving growth in laboratory and diagnostic markets aligns with the plan’s emphasis on expanding high‑growth, high‑margin verticals. KKR’s $250 million investment in January 2025, which gave the private‑equity firm a 12 % stake and board representation, underscores a shared goal of delivering over $200 million in operating‑income improvements through disciplined cost management and operational efficiencies.
Financially, Henry Schein delivered a strong Q3 2025 earnings beat, reporting adjusted earnings per share of $1.38 versus consensus of $1.27—a $0.11 or 8.7 % beat—while revenue rose to $3.34 billion, topping estimates of $3.28 billion. The beat was driven by robust demand in the dental and medical equipment segments, particularly in Europe, and by a favorable product mix that increased the contribution of high‑margin specialty items. In contrast, the company’s Q4 2024 results fell short of expectations, with adjusted EPS of $1.19 versus $1.21 and revenue of $3.19 billion versus $3.30 billion, largely due to foreign‑currency headwinds and a modest decline in legacy product sales.
In a statement, Lowery said, “I am honored to join Henry Schein at a pivotal moment. The company’s reputation for innovation and customer service, combined with a clear growth strategy, positions us to deliver significant value to clinicians and patients.” Chairman and outgoing CEO Stanley M. Bergman added, “Lowery’s experience and the partnership with KKR will accelerate our BOLD+1 plan and unlock the operating‑income improvement potential we identified.”
The leadership transition, coupled with KKR’s strategic investment, signals a renewed focus on operational excellence and high‑margin expansion. Management’s guidance for 2025 maintains a 2 % to 4 % sales growth outlook and a mid‑single‑digit adjusted EBITDA growth, reflecting confidence in the company’s ability to sustain momentum while executing cost‑control initiatives. The combined effect of a new CEO, a private‑equity partnership, and a clear growth roadmap positions Henry Schein to strengthen its competitive edge in the dental and medical markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.